Cellular and Molecular Neurobiology

, Volume 26, Issue 4–6, pp 577–589 | Cite as

Implication of Cannabinoids in Neurological Diseases

  • Angela Alsasua del ValleEmail author


1. Preparations from Cannabis sativa (marijuana) have been used for many centuries both medicinally and recreationally.

2. Recent advances in the knowledge of its pharmacological and chemical properties in the organism, mainly due to Δ9-tetrahydrocannabinol, and the physiological roles played by the endocannabinoids have opened up new strategies in the treatment of neurological and psychiatric diseases.

3. Potential therapeutic uses of cannabinoid receptor agonists include the management of spasticity and tremor in multiple sclerosis/spinal cord injury, pain, inflammatory disorders, glaucoma, bronchial asthma, cancer, and vasodilation that accompanies advanced cirrhosis. CB1 receptor antagonists have therapeutic potential in Parkinson's disease.

4. Dr. Julius Axelrod also contributed in studies on the neuroprotective actions of cannabinoids.


cannabinoids tetrahydrocannabinol epilepsy neurological diseases multiple sclerosis neuroprotective effects 


  1. Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Huffman, J. W., and Layward, L. (2000). Cannabinoids control spasticity and tremor in a MS model. Nature 404:84–87.PubMedCrossRefGoogle Scholar
  2. Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., and Di Marzo, V. (2001). Endocannabinoids control spasticity in a MS model. FASEB J. 15:300–302.PubMedGoogle Scholar
  3. Brotchie, J. M., Fox, S. H., and Henry, B. (1997). The cannabinoid receptor antagonist SR 141716A reduces L-dopa-induced dyskinesia in the MPTP-treated primate model of Parkinson's disease. Br. J. Pharmacol. 123:67–76.Google Scholar
  4. Brotchie, J. M. (2003). CB1 cannabinoid receptor signalling in Parkinson's disease. Curr. Opin. Pharmacol. 3:54–61.PubMedCrossRefGoogle Scholar
  5. Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Wroath, C., Parkin, S. G., Fox, P., Wright, D., Hobart, C., and Zajicek, P. (2004). Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study. Neurology 63(7):1245–1250.PubMedGoogle Scholar
  6. Croxford, J. L., and Miller, S. D. (2004). Towards cannabis and cannabinoid treatment of MS. Drugs Today (Barc) 40(8):663–676.CrossRefGoogle Scholar
  7. Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., and Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:605–613.PubMedGoogle Scholar
  8. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992). Isolation and structure of a brain constitutent that binds to the cannabinoid receptor. Science 258:1946–1949.PubMedCrossRefGoogle Scholar
  9. Engler, B., Freiman, I., Urbanski, M., and Szabo, B. (2005). Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse JPET. Scholar
  10. Ferguson, B., Matyszak, M. K., Esiri, M. M., and Perry, V. H. (1997). Axonal damage in acute MS lesions. Brain 120(3):393–399.PubMedCrossRefGoogle Scholar
  11. Fox, S. H., Henry, B., Hill, M., Crossman, A., and Brotchie, J. (2002). Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 17:1180–1187.PubMedCrossRefGoogle Scholar
  12. Frankel, J. P., Hughes, A., Lees, A. J., and Stern, G. M. (1990). Marijuana for parkinsonian tremor. J. Neurol. Neurosurg. Psychiatry 53:436–443.PubMedCrossRefGoogle Scholar
  13. Glass, M., Faull, R. L., and Dragunow, M. (1993). Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 56:523–527.PubMedCrossRefGoogle Scholar
  14. Glass, M., Dragunow, M., and Faull, R. L. (2000). The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97(3):505–519.PubMedCrossRefGoogle Scholar
  15. Glass, M. (2001). The role of cannabinoids in neurodegenerative diseases. Prog. Neuropsychopharmacol. Biol. Psychiatry 25(4):743–765.PubMedCrossRefGoogle Scholar
  16. Gross, D. W., Hamm, J., Ashworth, N. L., and Quigley, D. (2004). Marijuana use and epilepsy: Prevalence in patients of a tertiary care epilepsy center. Neurology 62(11):1924–1925.Google Scholar
  17. Gruber, A., and Poper, H. (1994). Cannabis psychotic disorder: Does it exist? Am. J. Addict. 3:72–83.CrossRefGoogle Scholar
  18. Guzmán, M. (2003). Neurons on cannabinoids: Dead or alive? Br. J. Pharmacol. 40:439–440.CrossRefGoogle Scholar
  19. Hampson, A. J., Grimaldi, M., Axelrod, J., and Wink, D. (1998). Cannabidiol and Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U.S.A. 95:8268–8273.PubMedCrossRefGoogle Scholar
  20. Howlett, A. C., Johnson, M. R., Melvin, L. S., and Milne, G. M. (1988). Nonclassical cannabinoid analgetics inhibit adenylate cyclase: Development of a cannabinoid receptor model. Mol. Pharmacol. 33:297–302.PubMedGoogle Scholar
  21. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., and Pertwee, R. G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54(2):161–202.PubMedCrossRefGoogle Scholar
  22. Iversen, L. (2003). Cannabis and the brain. Brain 126(6):1252–1270.PubMedCrossRefGoogle Scholar
  23. Jackson, S. J., Pryce, G., Diemel, L. T., Cuzner, M. L., and Baker, D. (2005). Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 134:261–268.PubMedCrossRefGoogle Scholar
  24. Jarai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. M., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, E., Razdan, R. K., Zimmer, A., and Kunos, G. (1999). Cannabinoid-induced mesenteric vasodilation through an endotelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A. 96:14136–14141.PubMedCrossRefGoogle Scholar
  25. Killestein, J., Uitdehaag, B. M. J., and Polman, C. H. (2004). Cannabinoids in MS: Do they have a therapeutic role? Drugs 64(1):1–11.PubMedCrossRefGoogle Scholar
  26. Kirk, J. M., Doty, F., and De Wit, H. (1998). Effects of expectancies on subjective responses to oral Δ9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 59(2):287–293.PubMedCrossRefGoogle Scholar
  27. Kofalvi, A., Rodrigues, R. J., Ledent, C., Mackie, K., Vizi, E. S., Cunha, R. A., and Sperlagh, B. (2005). Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: A combined immunochemical and pharmacological analysis. J. Neurosci. 25(11):2874–2884.PubMedCrossRefGoogle Scholar
  28. Koprowski, H., Zheng, Y. M., Heber-Katz, E., Fraser, N., Rorke, L., Fu, Z. F., Hanlon, C., and Dietzschold, B. (1993). In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc. Natl. Acad. Sci. U.S.A. 90:3024–3027.PubMedCrossRefGoogle Scholar
  29. Kunos, G., Batkai, S., Offertaler, L., Mo, F., Liu, J., Karcher, J., and Harvey-White, J. (2002). The quest for a vascular endothelial cannabinoid receptor. Chem. Phys. Lipids 121:45–56.PubMedCrossRefGoogle Scholar
  30. Lastres-Becker, I., Fezza, F., Cebeira, M., Bisogno, T., Ramos, J. A., Milone, A., Fernandez-Ruiz, J., and Di Marzo, V. (2001). Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport 12:2125–2129.PubMedCrossRefGoogle Scholar
  31. Lutz, B. (2004). On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem. Pharmacol. 68(9):1691–1698.PubMedCrossRefGoogle Scholar
  32. Malfitano, A. M., Matarese, G., and Bifulco, M. (2005). From cannabis to ndocannabinoids in MS: A paradigm of central nervous system autoimmune diseases. Curr. Drug Target CNS Neurol. Disord. 4(6):667–675.CrossRefGoogle Scholar
  33. Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutierrez, S. O., van der Stelt, M., Lopez-Rodriguez, M. L., Casanova, E., Schutz, G., Zieglgansberger, W., Di Marzo, V., Behl, C., and Lutz, B. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84–88.PubMedCrossRefGoogle Scholar
  34. Martin, B. R., Mechoulam, R., and Razdan, R. K. (1999). Discovery and characterization of endogenous cannabinoids. Life Science 65(6/7):573–595.CrossRefGoogle Scholar
  35. Martínez-Orgado, J., Fernandez-Frutos, B., Gonzalez, R., Romero, E., Uriguen, L., Romero, J., and Viveros, M. P. (2003). Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Mol. Brain Res. 114:132–139.PubMedCrossRefGoogle Scholar
  36. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564.PubMedCrossRefGoogle Scholar
  37. Mechoulam, R., and Gaoni, Y. (1965). A total synthesis of Δ9-tetrahydrocannabinol, the active constitutent of hashish. J. Am. Chem. Soc. 87:3273–3275.PubMedCrossRefGoogle Scholar
  38. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., Petrwee, R. G., Griffin, G., Bayewitch, M., Barg, J., and Vogel, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:83–90.PubMedCrossRefGoogle Scholar
  39. Mechoulam, R., Panikashvili, D., and Shohami, E. (2002). Cannabinoids and brain injury: Therapeutic implications. Trends Mol. Med. 8(2):58–61.PubMedCrossRefGoogle Scholar
  40. Miller, A. S., and Walker, J. M. (1995). Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. Eur. J. Pharmacol. 279:179–185.PubMedCrossRefGoogle Scholar
  41. Molina-Holgado, F., Lledo, A., and Guaza, C. (1997). Anandamide suppresses nitric oxide and TNFa responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 8:1929–1933.PubMedGoogle Scholar
  42. Morisset, V., and Laszlo, U. (2001). Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. J. Neurophysiol. 86(1):40–48.PubMedGoogle Scholar
  43. Muller-Vahl, K. R., Kolbe, H., Schneider, U., and Emrich, H. M. (1999). Cannabis in movement disorders. Forschende Komplementrmedizin 6:23–27.CrossRefGoogle Scholar
  44. Munro, S., Thomas, K. L., and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65.PubMedCrossRefGoogle Scholar
  45. Nagayama, T. A., Sinor, D., Simon, P., Chen, J., Graham, H., Jin, H. K., and Greenberg, D. A. (1999). Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19:2987–2995.PubMedGoogle Scholar
  46. Netzeband, J. G., Conroy, S. M., Parsons, K. L., and Gruol, D. L. (1999). Cannabinoids enhance NMDA-elicited Ca2+ signals in cerebellar granule neurons in culture. J. Neurosci. 19(20):8765–8777.PubMedGoogle Scholar
  47. Pertwee, R. G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74(2):129–180.PubMedCrossRefGoogle Scholar
  48. Pertwee, R. G. (1998). Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors. Biochem. Soc. Trans. 26(2):267–272.PubMedGoogle Scholar
  49. Piomelli, D., Giuffrida, A., Calignano, A., and Rodríguez de Fonseca, F. (2000). The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. 21:218–224.PubMedCrossRefGoogle Scholar
  50. Pope, H., Gruber, A., and Yurgelan-Todd, D. (1995). The residual neuropsychological effects of cannabis: The current status of research. Drug Alcohol Depend 38:25–34.Google Scholar
  51. Pryce, G., Zubair, A., Hankey, D., Jackson, S., Croxford, L., Pocock, J., Ledent, C., Petzold, A., Alan, J., Thompson, A. J., Gavin Giovannoni, G., Cuzner, M. L., and Baker, D. (2003). Cannabinoids inhibit neurodegeneration in models of MS. Brain 126(10):2191–2202.PubMedCrossRefGoogle Scholar
  52. Richfield, E. K., and Herkenham, M. (1994). Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 36:577–584.PubMedCrossRefGoogle Scholar
  53. Ries, R. K. (1993). The dually diagnosed patient with psychotic symptoms. J. Addict. Dis. 12(3):103–122.PubMedCrossRefGoogle Scholar
  54. Rodriguez de Fonseca, F., Del Arco, I., Bermudez-Silva, F. J., Bilbao, A., Cippitelli, A., and Navarro, M. (2005). The endocannabinoid system: Physiology and pharmacology. Alcohol Alcohol. 40(1):2–14.PubMedGoogle Scholar
  55. Romero, J., Lastres-Becker, I., de Miguel, R., Berrendero, F., Ramos, J. A., and Fernandez-Ruiz, J. (2002). The endogenous cannabinoid system and the basal ganglia. Biochemical, pharmacological, and therapeutic aspects. J. Pharmacol. Ther. 95(2):137–152.CrossRefGoogle Scholar
  56. Sañudo-Peña, M. C., Patrick, S. L., Khen, S., Patrick, R. L., Tsou, K., and Walker, J. M. (1998). Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci. Lett. 248:171–174.PubMedCrossRefGoogle Scholar
  57. Schwenkreis, P., and Tegenthoff, M. (2003). Therapeutic use of cannabinoids in neurology. Schmerz 17(5):367–373.PubMedCrossRefGoogle Scholar
  58. Shen, M., Piser, T. M., Seybold, V. S., and Thayer, S. A. (1996). Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16(14):4322–4334.PubMedGoogle Scholar
  59. Shen, M., and Thayer, S. A. (1998). Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54:459–462.PubMedGoogle Scholar
  60. Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P., Crossman, A. R., and Brotchie, J. M. (2001). Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study. Neurology 57(11):2108–2111.PubMedGoogle Scholar
  61. Skaper, S. D., Buriani, A., Dal Toso, R., Petrelli, L., Romanello, S., Facci, L., and Leon, A. (1996). The aliamide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamateparadigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. U.S.A. 93:3984–3989.PubMedCrossRefGoogle Scholar
  62. Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., Chambers, J. K., Randall, A. D., and Davis, J. B. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129(2):227–230.PubMedCrossRefGoogle Scholar
  63. Stella, N., Schweitzer, P., and Piomelli, D. (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773–778.PubMedCrossRefGoogle Scholar
  64. Tsou, K., Brown, S., Sanudo-Pena, M. C., Mackie, K., and Walker, J. M. (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393–411.PubMedCrossRefGoogle Scholar
  65. Twitchell, W., Brown, S., and Mackie, K. (1997). Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78:43–50.PubMedGoogle Scholar
  66. van der Stelt, M., Veldhuis, W. B., Maccarrone, M., Bar, P. R., Nicolay, K., Veldink, G. A., di Marzo, V., and Vliegenthsrt, J. F. (2002). Acute neuronal injury excitotoxicity, and the endocannabinoid system. Mol. Neurobiol. 26c:317–346.CrossRefGoogle Scholar
  67. Venderova, K., Ruzicka, E., Vorisek, V., and Visnovsky, P. (2004). Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms. Mov. Disord. 19(9):1102–1106.PubMedCrossRefGoogle Scholar
  68. Venderova, K., Brown, T. M., and Brotchie, J. M. (2005). Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. Exp. Neurol. 194(1):284–287.PubMedCrossRefGoogle Scholar
  69. Witkin, J. M., Tzavara, E. T., and Nomikos, G. G. (2005). A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav. Pharmacol. 16(5–6):315–331.PubMedCrossRefGoogle Scholar
  70. Wallace, M. J., Blair, R. E., Falenski, K. W., Martin, B. R., and De Lorenzo, R. J. (2003). The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 307:129–137.PubMedCrossRefGoogle Scholar
  71. White, R., Ho, W. S., Bottrill, F. E., Ford, W. R., and Hiley, C. R. (2001). Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br. J. Pharmacol. 134:921–929.PubMedCrossRefGoogle Scholar
  72. Williamson, E. M., and Evans, F. J. (2000). Cannabinoids in clinical practice. Drugs 60(6):1303–1314.PubMedCrossRefGoogle Scholar
  73. Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., and Bonner, T. I. (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 96(10):5780–5785.PubMedCrossRefGoogle Scholar
  74. Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sørgård, M., Di Marzo, V., Julius, D., and Högestätt, E. D. (1999). Vanilloid receptors on sensory nerves mediated the vasodilator action of anandamide. Nature 400:452–457.PubMedCrossRefGoogle Scholar
  75. Zygmunt, P. M., Andersson, D. A., and Högestätt, E. D. (2002). Δ9-Tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J. Neurosci. 22(11):4720–4727.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Dpto. Farmacología, Facultad de MedicinaUniversidad Complutense de MadridMadridSpain

Personalised recommendations